Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Research & Development (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Research & Development for 10 consecutive years, with $8.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 68.0% year-over-year to $8.6 million, compared with a TTM value of $61.7 million through Sep 2025, down 26.95%, and an annual FY2024 reading of $96.8 million, up 88.1% over the prior year.
  • Research & Development was $8.6 million for Q3 2025 at Spero Therapeutics, down from $10.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $28.8 million in Q4 2024 and bottomed at $7.4 million in Q3 2022.
  • Average Research & Development over 5 years is $15.4 million, with a median of $15.1 million recorded in 2022.
  • The sharpest move saw Research & Development surged 149.47% in 2024, then crashed 68.0% in 2025.
  • Year by year, Research & Development stood at $17.2 million in 2021, then fell by 12.4% to $15.1 million in 2022, then rose by 9.73% to $16.6 million in 2023, then soared by 74.16% to $28.8 million in 2024, then plummeted by 70.19% to $8.6 million in 2025.
  • Business Quant data shows Research & Development for SPRO at $8.6 million in Q3 2025, $10.7 million in Q2 2025, and $13.6 million in Q1 2025.